Cancer neoantigens as potential targets for immunotherapy.

doi:10.1007/s10585-021-10091-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Cancer neoantigens as potential targets for immunotherapy.

Clinical & experimental metastasis - 1 Feb 2022

Ma Weijie, Pham Brian, Li Tianhong

Abstract excerpt

Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and programed cell death protein 1 (PD-1) or its ligand PD-L1 have increased the survival and cure rates for patients with many cancer types in various disease settings. However, only 10-40% of cancer patients benefited from these ICIs, of whom ~ 20% have treatment interruption or discontinuation due to...

Topics

Biomarkers, Tumor
Humans
Immunotherapy
Medical Oncology
Microsatellite Instability
Mutation
Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 33950415
DOI: 10.1007/s10585-021-10091-1
PMCID: PMC8097110

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics